Intercell and Romark join forces in combining therapies against Hepatitis C
26-Oct-2010 -
Intercell AG and Romark Laboratories L.C. announced plans to commence clinical trials of Intercell's investigational therapeutic Hepatitis C virus (HCV) vaccine, IC41, in combination with Romark's antiviral drug,
nitazoxanide, during the first half of 2011.
Intercell's vaccine candidate has ...
clinical trials
hepatitis C
laboratories
+2